Announcements

AATB has learned that the US Food and Drug Administration (FDA) has reissued the following guidance documents as drafts, with a public comment period open through July 7, 2025.

On April 18, 2025, the White House Office of Management and Budget (OMB) received the two guidance documents from the US Food and Drug Administration (FDA) for final review under the Administration’s mandate to evaluate guidance issued during the previous administration.

AATB is seeking nominations for the AATB Board of Governors in the following leadership positions: Chairperson-Elect, Secretary-Treasurer, and At-Large Governors (2).

On Friday, April 11, the Centers for Medicare & Medicaid Services (CMS) announced that the final Local Coverage Determinations (LCDs) for Skin Substitute Grafts/Cellular and Tissue-Based Products for the Treatment of Diabetic Foot Ulcers and Venous Leg Ulcers will now take effect on January 1, 2026.

As part of our continued advocacy efforts, AATB—alongside AOPO and EBAA—sent a joint letter today to newly confirmed FDA Commissioner Dr. Marty Makary urging the immediate rescission of two guidance documents issued as final on January 6, 2025.

Join industry professionals from blood centers, tissue banks, and organ procurement organizations across the country for two days of valuable networking, knowledge-sharing, and collaboration.

AATB commends Representatives John Moolenaar (R-MI) and Debbie Dingell (D-MI) for reintroducing the Shandra Eisenga Human Cell and Tissue Product Safety Act, a vital piece of legislation aimed at preventing tuberculosis (TB) infections linked to tissue transplants.

Earlier this week, AATB representatives and members had the incredible opportunity to visit Capitol Hill, to advocate for key issues impacting the tissue banking community.

AATB is pleased to announce that we will no longer charge institutional members a supplemental fee for satellite site inspections conducted as part of the routine three-year accreditation cycle.